logo
logo
VCEL stock ticker logo

Vericel Corporation

NASDAQ•VCEL
CEO: Mr. Dominick C. Colangelo Esq.
セクター: Healthcare
業種: Biotechnology
上場日: 1997-02-04
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
連絡先情報
64 Sidney Street, Cambridge, MA, 02139, United States
617-588-5555
vcel.com
時価総額
$1.91B
PER (TTM)
88.6
24.5
配当利回り
--
52週高値
$43.57
52週安値
$28.95
52週レンジ
58%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

深度リサーチ

財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし